http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
요추 추간판 절제술 후 발생한 화농성 척추염에 대한 Chuinard & Peterson 골 이식술을 이용한 전방 유합술 및 경피적 후관절 나사못 고정술
장상범,이상호,이승철,신송우,김원중 대한척추신경외과학회 2004 Neurospine Vol.1 No.1
Objective: To describe the surgical techniques and the preliminary results of anterior fusion with Chuinard & Peterson bone graft and posterior percutaneous facet screw fixation for pyogenic spondylitis following lumbar discectomy. Methods: From April to October 2003, five consecutive patients underwent anterior lumbar interbody fusion with Chuinard & Peterson bone graft and posterior percutaneous facet screw fixation for the treatment of pyogenic spondylitis that developed after primary lumbar disc surgery. There were three males and two females. The mean age was 49.8 years(range, 28-75 years). Three patients had persistent inflammation with neurologic deterioration and two had severe back pain despite of less invasive interventions. The mean interval from the primary operation to fusion was 3.3 months(range, 1.5~7 months). All patients were allowed to ambulate immediate postoperatively with a lumbar orthosis, which was kept for three months. Intravenous and oral antibiotics were continued until hematologic profiles normalized. All patients were followed up clinically and radiologically. Results: The mean operating time, blood loss, and post-operative hospital stay were 210 mins, 890 ml, and 27 days, respectively. Four patients showed a solid fusion at 3 monthes and one patient showed fusion at 4 monthes postoperatively. M patients showed remission of infection and significant clinical improvement of back pain. Conclusions: Anterior fusion using Chuinard & Peterson bone graft and posterior facet screw fixation may be employed for postoperative pyogenic spondylitis without prolonged cast immobilization or risk of persistent infection caused by instrumentation.
白鏞舜,張祥範,이진무 中央醫學社 1963 中央醫學 Vol.5 No.3
A case of partent urachus is presented with its review of literatures. It is the second case reported in Korea, the first case reported by Yonsei University. Medical School in June, 1960. It was associated with other congenital anomalies such as agenesis of gher left kidney, ureter and trigon of the bladder, and tuberculous infection in the urachus. Embryologically, it is considered that the urachus is probably originated from the cloaca rather than allantois.
비스테로이드성 소염진통제 β -Cyclodextrin-Piroxicam의 유효성 및 안전성에 관한 비교연구 : Double Blind Study
석세일,이상훈,김상수,장상범 中央醫學社 1995 中央醫學 Vol.60 No.2
The authors have conducted a clinical study on the safety and efficacy with newly developed β-Cyclodextrin-Piroxicam(Brexine®) in 60 cases of the patients of osteoarthritis and rheumatoid arthritis during six months from June 1994 to November 1994. The study was a randomized controlled study of 19 β-Cyclodextrin-Piroxicam versus Piroxicam(Dispersible tablet) assessing the clinical efficacy and side effects in 30 patients receiving daily 20 mg of β -Cyclodextrin-Piroxicam and in 30 patients receiving daily 20 mg of Piroxicam(Dispersible tablet). Total period of administration was eight weeks. Therapeutic efficacy and tolerability after 4, 8 weeks were evaluated by themselves and doctors. The average age of patients was 55.8 years and 13 cases were men and 47 cases were women. The sites of pain were knee in 28 cases, low back in 27 cases, neck in 5 cases, hand and wrist in 5 cases and others in 4 cases. The results were as follows ; 1. Most patients showed significant improvements in pain scale, morning stiffness and tenderness in both the β-Cyclodextrin-Piroxicam and the Piroxicam group. 2. There were four cases of gastrointestinal intolerance in the Piroxicam group and two in the β-Cyclodextrin-Piroxicam group. 3. The efficacy of Piroxicam at 8 weeks was 70.0 % and tolerance was 86.7 % and the efficacy of β-Cyclodextrin-Piroxicam was 83.3 % and tolerance was 93.3 %. In conclusion, β-Cvclodextrin-Piroxicam, used in the treatment of osteoarthritis and rheumatoid arthritis, appears to be a effective and well tolerated drug compared to Piroxicam.